EA201690099A1 - Устойчивая жидкая композиция, содержащая amg-416 (велкальцетид) - Google Patents

Устойчивая жидкая композиция, содержащая amg-416 (велкальцетид)

Info

Publication number
EA201690099A1
EA201690099A1 EA201690099A EA201690099A EA201690099A1 EA 201690099 A1 EA201690099 A1 EA 201690099A1 EA 201690099 A EA201690099 A EA 201690099A EA 201690099 A EA201690099 A EA 201690099A EA 201690099 A1 EA201690099 A1 EA 201690099A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition containing
liquid composition
velcalcetide
amg
sustainable liquid
Prior art date
Application number
EA201690099A
Other languages
English (en)
Other versions
EA030220B1 (ru
Inventor
Дерек Маклин
Цюнь Инь
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690099(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201690099A1 publication Critical patent/EA201690099A1/ru
Publication of EA030220B1 publication Critical patent/EA030220B1/ru

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04D—NON-POSITIVE-DISPLACEMENT PUMPS
    • F04D25/00—Pumping installations or systems
    • F04D25/02—Units comprising pumps and their driving means
    • F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
    • F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
    • F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
    • F01D15/10—Adaptations for driving, or combinations with, electric generators

Abstract

Предлагаются жидкая композиция, содержащая пептидный агонист кальций-чувствительного рецептора, а также способ изготовления и использование данной композиции.
EA201690099A 2013-06-28 2014-06-27 Устойчивая жидкая композиция, содержащая amg-416 (этелкалцетид) EA030220B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840618P 2013-06-28 2013-06-28
PCT/US2014/044622 WO2014210489A1 (en) 2013-06-28 2014-06-27 Stable liquid formulation of amg 416 (velcalcetide)

Publications (2)

Publication Number Publication Date
EA201690099A1 true EA201690099A1 (ru) 2016-06-30
EA030220B1 EA030220B1 (ru) 2018-07-31

Family

ID=51213030

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690099A EA030220B1 (ru) 2013-06-28 2014-06-27 Устойчивая жидкая композиция, содержащая amg-416 (этелкалцетид)

Country Status (38)

Country Link
US (4) US9820938B2 (ru)
EP (3) EP3246017B1 (ru)
JP (1) JP6027708B2 (ru)
KR (1) KR102231957B1 (ru)
CN (2) CN105764487A (ru)
AP (1) AP2015008936A0 (ru)
AR (1) AR096773A1 (ru)
AU (1) AU2014302122B2 (ru)
CA (1) CA2916222C (ru)
CL (1) CL2015003738A1 (ru)
CR (2) CR20160002A (ru)
CY (1) CY1120811T1 (ru)
DK (1) DK3013318T3 (ru)
EA (1) EA030220B1 (ru)
ES (1) ES2633989T3 (ru)
HK (1) HK1222557A1 (ru)
HR (1) HRP20171092T1 (ru)
HU (1) HUE034209T2 (ru)
IL (1) IL243210B (ru)
JO (1) JO3817B1 (ru)
LT (1) LT3013318T (ru)
MA (1) MA38724B1 (ru)
ME (1) ME02818B (ru)
MX (1) MX2015017952A (ru)
MY (1) MY180276A (ru)
PE (2) PE20160549A1 (ru)
PH (1) PH12015502816A1 (ru)
PL (1) PL3013318T3 (ru)
PT (1) PT3013318T (ru)
RS (1) RS56238B1 (ru)
SG (1) SG11201510647TA (ru)
SI (1) SI3013318T1 (ru)
TN (1) TN2015000569A1 (ru)
TW (1) TWI635874B (ru)
UA (1) UA115373C2 (ru)
UY (1) UY35636A (ru)
WO (1) WO2014210489A1 (ru)
ZA (1) ZA201600238B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034209T2 (en) 2013-06-28 2018-02-28 Amgen Inc AMG 416 stable liquid preparation (velcalcetide)
EP3708576B1 (en) 2014-04-03 2023-02-22 Amgen Inc. Method for preparing amg 416
US10858389B2 (en) 2015-03-26 2020-12-08 Amgen Inc. Solution phase method for preparing etelcalcetide
CN106137979A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种冻干粉针剂及其制备方法
CN106928320B (zh) 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN110054662B (zh) * 2018-01-18 2021-03-02 成都圣诺生物制药有限公司 一种固相合成Etelcalcetide的方法
AU2021270318A1 (en) 2020-05-15 2022-12-15 Amgen Inc. Methods of treating left ventricle hypertrophy
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
WO2022034545A1 (en) * 2020-08-14 2022-02-17 Aurobindo Pharma Limited Etelcalcetide formulations for parenteral use
AU2022268916A1 (en) 2021-05-06 2023-11-09 Amgen Inc. Etelcalcetide formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196314T1 (de) 1996-10-25 2000-09-15 Us Health Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
WO2004105781A2 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
AU2007325387B2 (en) 2006-11-16 2014-04-03 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
JP2010516707A (ja) 2007-01-19 2010-05-20 カイ ファーマシューティカルズ インコーポレーティッド ペプチド組成物の安定性および送達効率を上昇させるための修飾方法
ES2412707T5 (es) 2009-06-19 2023-06-12 Procter & Gamble Composición detergente líquida para lavado de vajillas a mano
ES2607954T3 (es) * 2009-07-29 2017-04-04 Kai Pharmaceuticals, Inc. Agentes terapéuticos para reducir los niveles de hormona paratiroidea
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
BR112013031539A2 (pt) 2011-06-08 2019-07-30 Kai Pharmaceuticals Inc agentes terapêuticos para regular fósforo sérico
EP2776129B2 (en) 2011-11-10 2020-06-17 Kai Pharmaceuticals, Inc. Compositions for use in the treatment of chronic kidney disease-mineral bone disorder characterized by soft tissue calcification
HUE034209T2 (en) 2013-06-28 2018-02-28 Amgen Inc AMG 416 stable liquid preparation (velcalcetide)
EP3708576B1 (en) * 2014-04-03 2023-02-22 Amgen Inc. Method for preparing amg 416

Also Published As

Publication number Publication date
SG11201510647TA (en) 2016-01-28
EP3246017A1 (en) 2017-11-22
PL3013318T3 (pl) 2018-03-30
CA2916222A1 (en) 2014-12-31
PE20160549A1 (es) 2016-06-15
MA38724A1 (fr) 2017-03-31
CN105764487A (zh) 2016-07-13
US20160220486A1 (en) 2016-08-04
US9820938B2 (en) 2017-11-21
JP6027708B2 (ja) 2016-11-16
ZA201600238B (en) 2017-05-31
EP3878433A1 (en) 2021-09-15
CL2015003738A1 (es) 2016-12-09
AP2015008936A0 (en) 2015-12-31
US20180080452A1 (en) 2018-03-22
IL243210A0 (en) 2016-02-29
MA38724B1 (fr) 2017-11-30
US11162500B2 (en) 2021-11-02
PE20210413A1 (es) 2021-03-04
ES2633989T3 (es) 2017-09-26
EP3013318B1 (en) 2017-04-19
SI3013318T1 (sl) 2017-11-30
CA2916222C (en) 2021-05-18
RS56238B1 (sr) 2017-11-30
KR102231957B1 (ko) 2021-03-25
IL243210B (en) 2020-02-27
WO2014210489A1 (en) 2014-12-31
TN2015000569A1 (en) 2017-04-06
CR20160061A (es) 2016-09-28
PT3013318T (pt) 2017-07-24
MY180276A (en) 2020-11-26
UY35636A (es) 2015-01-30
HRP20171092T1 (hr) 2017-10-06
CR20160002A (es) 2018-02-13
MX2015017952A (es) 2016-10-28
US10344765B2 (en) 2019-07-09
TWI635874B (zh) 2018-09-21
PH12015502816B1 (en) 2016-03-21
DK3013318T3 (en) 2017-08-07
KR20160043954A (ko) 2016-04-22
JP2016523916A (ja) 2016-08-12
US20190285074A1 (en) 2019-09-19
EA030220B1 (ru) 2018-07-31
CN114376970A (zh) 2022-04-22
UA115373C2 (uk) 2017-10-25
US20220042515A1 (en) 2022-02-10
HK1222557A1 (zh) 2017-07-07
PH12015502816A1 (en) 2016-03-21
BR112015032615A2 (pt) 2017-07-25
EP3013318A1 (en) 2016-05-04
JO3817B1 (ar) 2021-01-31
LT3013318T (lt) 2017-09-11
AU2014302122A1 (en) 2016-01-21
TW201542239A (zh) 2015-11-16
AR096773A1 (es) 2016-02-03
US11959486B2 (en) 2024-04-16
AU2014302122B2 (en) 2018-12-06
HUE034209T2 (en) 2018-02-28
CY1120811T1 (el) 2019-12-11
EP3246017B1 (en) 2021-03-24
NZ715403A (en) 2020-10-30
ME02818B (me) 2018-01-20

Similar Documents

Publication Publication Date Title
EA201690099A1 (ru) Устойчивая жидкая композиция, содержащая amg-416 (велкальцетид)
GEP20207182B (en) Cyclic di-nucleotide compounds as sting agonists
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CR20150618A (es) Anticuerpos receptores de antitransferina y métodos de uso
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591748A1 (ru) Модуляторы p2x7
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201591962A1 (ru) Ингибиторы акк и их применение
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201592239A1 (ru) Многокомпонентная система для изготовления раствора гидрокарбоната кальция, подходящая для реминерализации обессоленной воды и природной мягкой воды
EA201592245A1 (ru) Устройство для приготовления раствора гидрокарбоната кальция, применимого для реминерализации воды
EA201690036A1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM